# RESOLUTE China RCT

Study · id `cardio:ct-nct01334268` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01334268](<https://clinicaltrials.gov/study/NCT01334268>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01334268

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.

## Technical summary

Registry record NCT01334268. Randomized; single masking; primary purpose treatment. Start 2011-09 (actual); primary completion 2012-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 400 participants (enrolled count; ClinicalTrials.gov record NCT01334268, source copy `cardio:ctgov-nct01334268-2017-10-18`, retrieved 2026-10-26)
- Started: 2011-09 (actual) (ClinicalTrials.gov record NCT01334268, source copy `cardio:ctgov-nct01334268-2017-10-18`, retrieved 2026-10-26)
- Primary completion: 2012-11 (actual) (ClinicalTrials.gov record NCT01334268, source copy `cardio:ctgov-nct01334268-2017-10-18`, retrieved 2026-10-26)
- Completion: 2017-06-30 (actual) (ClinicalTrials.gov record NCT01334268, source copy `cardio:ctgov-nct01334268-2017-10-18`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01334268, source copy `cardio:ctgov-nct01334268-2017-10-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01334268-2017-10-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: RESOLUTE China RCT
- Acronym: R-China RCT
- Condition: Ischemic Heart Disease
- Condition: Stenotic Coronary Lesion
- Condition: Cardiovascular Diseases
- Condition: Arteriosclerosis
- Condition: Coronary Artery Disease
- Intervention (Device): Taxus Liberte Paclitaxel-Eluting Coronary Stent System
- Intervention (Device): Resolute Zotarolimus-Eluting Coronary Stent System
- Lead sponsor: Medtronic Vascular
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Medtronic Vascular (`cardio:org-medtronic-vascular`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial (`cardio:pubmed-23523240`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 8d5f989cab786cc30055c35adf6f5f0b0781ad5cc5dd8dbdd55c9e118898831b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
